Proove CEO and Founder Brian Meshkin Selected as a Finalist for the ACG 21st Annual Awards
Irvine, CA (PRWEB) March 15, 2016 -- Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is pleased to announce that its CEO and Founder, Brian Meshkin, has been selected as a Finalist for the 21st ACG Awards in Orange County. In the category of Innovation, Meshkin was selected by a distinguished panel of judges from the Association for Corporate Growth Orange County chapter ("ACG-OC").
The ACG-OC awards program honors the highest performing companies and entrepreneurs in Orange County.
Award winners will be announced at a special ACG-OC Awards Gala on May 5th, 2016. Out of more than 100 nominations, 30 finalists were selected to make it to the finalist stage.
“Orange County is an incredible business community and it is an incredible honor for me and the team at Proove to receive this recognition,” states Meshkin. “At Proove, we are committed to using innovative technology to address the unresolved epidemic of pain in America and the tragic epidemic of prescription drug abuse.”
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Genevieve McCormick, Proove Biosciences, http://www.proove.com, +1 949-556-7239, [email protected]
Share this article